DOCUMENTS

98

 

NOTICES

156

 

 

MOTS CLES

Adalimumab Biosimilar Pharmaceuticals Antimicrobiens Epidemiology Beta-lactam antibiotics Alitretinoin Biomarkers Sipuleucel-T Ankylosing Endocrine toxicity Antimicrobial Stewardship Axial spondyloarthritis Placebo Ethics Systematic review Adverse side effects Etanercept Psoriasis Amyloidosis Anxiety Arrhythmia Drug reaction Ankylosing spondylitis Pregnancy Accelerometer Stability Antibiotic misuse Network meta-analysis Apremilast Immune checkpoint inhibitors Addiction Bacterial Burden Pharmacoepidemiology Adolescent Access to care Drug survival Apre-milast Aging Auto-Diagnostic Psoriatic arthritis Sacroiliitis Antibiotic resistance Biologics Alcohol COVID-19 Anticancer drugs Spondylitis Biomédicaments Azathioprine Pharmacovigilance Dermatology Vigibase® Meta-Analysis Infliximab BTK protein Biologic drug Atopic dermatitis Quality of life Biological Therapy Abus d'antibiotiques Management Biologic ArtThese Arthritis Auto-immune hepatitis ASDAS Biological therapy Anti-HCV Direct Acting Antivirals DAA Autoimmunity Glucocorticoids Autoimmune diseases Graft-versus-host disease Treatment Angiotensin-converting enzyme inhibitors Primary adrenal insufficiency Acute Myeloid Leukaemia AML Antimicrobial resistance Antimicrobials Cardiomyopathy Cancer Antibiotics Cardiotoxicity Immunotherapy Atrial fibrillation Immune-related adverse events Prostate cancer Anti-TNF Angiotensin receptor blockers Anxiété Méta-Analyse Spondyloarthritis Ustekinumab Anti-Bacterial Agents Bacterial rhinosinusitis Biologic therapy Albinism Pharmaco-Épidémiologie Cardio-oncology Intensive care

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS